Cardiff Oncology Business Summary

Cardiff Oncology, Inc. (CRDF) is a clinical-stage biotechnology company primarily focused on developing precision medicine therapies for oncology by leveraging Polo-like Kinase 1 (PLK1) inhibition. The company operates as a research and development entity, generating minimal current revenue—approximately $501,000 trailing twelve-month as of late 2025—primarily through royalties on legacy licensed technologies and interest income. Its business model is centered on the clinical advancement and eventual commercialization or licensing of its lead therapeutic candidate, onvansertib, an oral selective PLK1 inhibitor. The company’s primary business segments are defined by its clinical programs, which target high-unmet-need indications including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), and triple-negative breast cancer (TNBC). In the competitive landscape, Cardiff Oncology operates alongside larger oncology-focused firms such as Jazz Pharmaceuticals, Kite Pharma (Gilead), and Advanced Accelerator Applications (Novartis), positioning itself as a specialized player focusing on overcoming treatment resistance through a unique, validated biological mechanism. The company’s leadership underwent a significant transition in early 2026 to support its move into late-stage clinical development. Dr. Mani Mohindru, a seasoned biotech executive and former equity research analyst at UBS and Credit Suisse, currently serves as the interim Chief Executive Officer. Technical and clinical strategy is led by Chief Medical Officer Dr. Roger Sidhu, who joined in 2025 with over 20 years of experience from Treadwell Therapeutics and Amgen. Financial operations are overseen by Brigitte Lindsay, who was promoted to Chief Accounting Officer in January 2026 after 14 years with the firm. The company, originally founded in 1999 as Trovagene, is governed by a board chaired by Dr. Rodney S. Markin and includes notable independent directors such as Lâle White. Cardiff Oncology maintains a strong institutional investor base, with significant positions held by BlackRock, Vanguard Group, and Laurion Capital Management.